We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (383)
- Scheduling (national classification system) (164)
- Safety monitoring and information (26)
- Advertising (25)
- COVID-19 (11)
- Manufacturing (11)
- Medicinal cannabis hub (6)
- Clinical trials (5)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
758 result(s) found, displaying 51 to 75
-
Scheduling decisions (interim)Interim decisions on proposed amendments to the Poisons Standard closing 4 April 2025
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsAdvisory Committee on Vaccines meeting statement for meeting 50 held 4 December 2024
-
Meeting statementsAdvisory Committee on Vaccines Statement 51 for meeting held 5 February 2025
-
Meeting statementsAdvisory Committee on Vaccines meeting statement 49 for meeting held 2 October 2024
-
Meeting statementsMeeting statement from the 15th Consumer Working Group meeting that took place on 8 November 2024.
-
Scheduling decisions (interim)We have reopened the consultation on the interim decision regarding IV potassium in recognition of the broad impact of the proposed changes
-
Scheduling decisions (final)This web publication constitutes a notice for the purposes of regulations 42ZCZS of the Therapeutic Goods Regulations 1990 (the Regulations).
-
Corporate reportsThis report provides an overview of pharmacovigilance inspection deficiencies in 2022, including a comparison to results from previous reporting periods.
-
Scheduling decisions (final)This web publication constitutes a notice for the purposes of regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations).
-
Corporate reportsThe findings will inform the need for any risk management actions to ensure public safety.
-
Scheduling decisions (final)Publication of the decisions made by a delegate of the Secretary in relation to to nicotinic acid.
-
Corporate reportsThis plan outlines our compliance and education priorities for 2024-2025.
-
Meeting statementsRead the meeting statement from 12 December 2024 meeting of the Advisory Committee on Medical Devices.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsCommunique from the 1st meeting of the Human Research Ethics Committee and TGA Clinical Trials Discussion Forum, 27 November 2024
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 14 March 2024
-
Scheduling decisions (final)This web publication constitutes a notice for the purposes of regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations).
-
Scheduling decisions (interim)We are seeking submissions for a consultation on the interim decisions for IV potassium salts and nicotinic acid.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Corporate reportsRead our 2024 stakeholder survey report, which aims to improve the way we work with our stakeholders.
-
Meeting statementsCommunique from the meeting of the TGACC
-
Summary report of residual DNA and endotoxin on COVID-19 mRNA vaccines conducted by TGA Laboratories
TGA laboratory testing reportsThe TGA has conducted a comprehensive evaluation of the residual DNA and endotoxin levels in the two mRNA vaccines supplied in Australia - Comirnaty (Pfizer) and Spikevax (Moderna). -
Corporate reportsWe commissioned the Health Design Lab to conduct market research to better understand the individual consumer, pharmacist and prescriber experiences of shortages and discontinuations.
-
Meeting statementsAdvisory Committee on Medicines meeting statement